Loading stock data…
Anbio Biotechnology (NNNN)
$13.55-0.98 (-6.74%)
Market ClosedLast close Jun 29
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Anbio Biotechnology in the Healthcare sector is trading at $13.55 with a market capitalization of $1.3B. The stock is currently near its 52-week low of $10.50, remaining 50.2% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 32) — potential for technical mean-reversion
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | — | — | — | — | — |
Peer Comparison
JNJUNHPFE
Fundamentals
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isotherm...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.25B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
190.07
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-
Volume
Today's trading volume
34,576
Recent News
US Undiscovered Gems To Watch In May 2026
The United States market has shown robust performance recently, climbing 1.8% in the last week and up 28% over the past year, with earnings anticipated to grow by 17% annually in the coming years. In this thriving environment, identifying stocks that combine strong fundamentals with growth potential can uncover hidden opportunities for investors seeking to capitalize on these positive trends.
Discover 3 Undiscovered Gems in the US Market
The United States market has experienced a notable rise, climbing 1.8% in the last week and up 28% over the past year, with earnings projected to grow by 17% annually. In such a robust environment, identifying stocks that combine strong fundamentals with growth potential can uncover promising opportunities for investors seeking to capitalize on these favorable conditions.
Uncovering US Market's 3 Undiscovered Gems With Potential
The United States market has experienced a notable rise, with a 1.3% increase over the last week and a substantial 28% gain in the past year, while earnings are projected to grow by 17% annually in the coming years. In such an environment, identifying stocks that combine robust fundamentals with untapped potential can offer intriguing opportunities for investors seeking to capitalize on these favorable conditions.
Discovering US Undiscovered Gems In May 2026
Over the last 7 days, the United States market has remained flat, yet it has seen a remarkable increase of 27% over the past year with earnings forecasted to grow by 17% annually. In such a dynamic environment, identifying stocks that are not only resilient but also poised for growth can uncover hidden opportunities in an investor's portfolio.
Undiscovered Gems in the US Market May 2026
In the last week, the United States market has stayed flat despite being up 27% over the past year, with earnings forecasted to grow by 17% annually. In this environment, identifying stocks with strong growth potential and solid fundamentals can lead to uncovering hidden opportunities that may not yet be widely recognized.